Clinical Trials Logo

Clinical Trial Summary

Within the next decade, pancreatic ductal adenocarcinoma (PDAC) is expected to rise to the second leading cause of cancer-related mortality. To increase the survival, various peri-operative treatments have been tested, and adjuvant FOLFIRINOX or gemcitabine plus capecitabine is now standard of care after surgical resection for localized PDAC. Even with superior survival among various disease extent of PDAC, resectable PDAC still shows poor outcomes with surgery followed by adjuvant chemotherapy. This phase II study is investigating the role of modified-FOLFIRINOX as neoadjuvant treatment for resectable PDAC.

Clinical Trial Description

This phase II study is designed to evaluate the efficacy and safety of modified FOLFIRINOX as neoadjuvant treatment for resectable pancreatic cancer. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT05066802
Study type Interventional
Source Yonsei University
Contact Choong-kun Lee
Phone +82-2-2228-8133
Email [email protected]
Status Recruiting
Phase Phase 2
Start date May 11, 2020
Completion date May 31, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT04927780 - Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer Phase 3
Not yet recruiting NCT04940286 - Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer Phase 2
Completed NCT00600002 - Administration as a Biological Adjuvant in Clinically-Staged, Resectable Pancreatic Adenocarcinoma Phase 1
Recruiting NCT03251365 - Intrabdominal Hyperthermic Chemotherapy and Pancreatic Cancer Phase 2/Phase 3
Recruiting NCT04340141 - Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer Phase 3
Active, not recruiting NCT03273374 - Intraoperative Radiation Therapy for Resectable Pancreatic Cancer Phase 2
Not yet recruiting NCT04915417 - Neoadjuvant Stereotactic Ablative Radiotherapy for Pancreatic Ductal Adenocarcinoma N/A
Recruiting NCT04858334 - A Randomized Study of Olaparib or Placebo in Patients With Surgically Removed Pancreatic Cancer Who Have a BRCA1, BRCA2 or PALB2 Mutation, The APOLLO Trial Phase 2